Lumakras
sotorasib · KRAS G12CDerivation not stated; clinical exposures at 180-960 mg were below those at the rat STD10 but above those at the dog HNSTD
The public FDA and EMA reviews of Inqovi don't say how the first human dose was chosen. That rationale is in the IND, which is confidential, so it is missing for most approved products.
HNSTD/STD10 is the method used for anticancer drugs in patients: the start dose is one-sixth of the highest non-severely toxic dose (HNSTD) in non-rodents, or one-tenth of the dose severely toxic to 10% of rodents (STD10), scaled by body surface area. The aim is a dose that is pharmacologically active yet reasonably safe.
NOAEL / key findings: Reversible myelosuppression; reversible reproductive tract effects from cedazuridine (FDA multi-discipline review, p. 61)